Skip to main content
Premium Trial:

Request an Annual Quote

Serono Pays Inpharmatica $1.5M As Part of Newly Expanded Proteomics Alliance

NEW YORK, Nov. 16 (GenomeWeb News) - Inpharmatica and Serono have expanded for a third time a collaboration to develop secreted proteins using Inpharmatica's PharmaCarta platform, the firms said today.

 

Terms of the expanded deal call for Serono to pay Inpharmatica $1.5 million for granting Serono "additional rights" to Inpharmatica's protein sequences.

 

Additionally, Inpharmatica stands to gain undisclosed up-font payments, milestone payments, and royalties from any resulting products, the companies said.

 

The original two-year deal, struck in 2001, was expanded by one year in January 2003, and again for a single year in August 2003.

 

The recent expansion, which extends the alliance for an additional year, will seek to validate the more than 200 protein sequences the companies have jointly identified.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.